top of page
  • ODI Pharma

ODI Pharma Group announces consolidation under Swedish holding company, ODI Pharma AB

Zug/Switzerland, August 2nd, 2019 - The board of ODI Pharma Schweiz AG announces that its operations will be consolidated shortly under a Swedish holding company. All subsidiaries, including ODI Pharma Polska Sp. z o.o. will then be owned by the Swedish holding company. The shareholder structure of the group remains unchanged.

About ODI Pharma Group

ODI Pharma Group, based on it's European network, subsidiaries and affiliates, is a producer of pharmaceutical cannabis products with a focus on distribution to medicinal and recreational markets in Europe. The main focus of ODI Pharma is on the medicinal cannabis products that are sold to clients and patients through ODI Pharma's relationships to pharmacies and wholesale distributors.

ODI Pharma Group was founded and is lead by a team of professionals that benefits from it's excessive experience as doctors, researchers, investors and corporate managers.

ODI Pharma Group strives to improve the life of its patients and clients by providing state-of-the-art product, initiating and supporting research and promoting alternative ways of medication.

Forward Looking Information

Certain statements in this press release contain forward-looking information (collectively referred to herein as the "Forward-Looking Statements") within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify Forward-Looking Statements. In particular, but without limiting the forgoing, this press release contains Forward-Looking Statements pertaining to: (i) the expected consolidation under a Swedish holding company and related transactions.

Although ODI Pharma believes that the Forward-Looking Statements are reasonable, they are not guarantees of future results, performance or achievements. A number of factors or assumptions have been used to develop the Forward-Looking Statements. Actual results, performance or achievements could vary materially from those expressed or implied by the Forward-Looking Statements should assumptions underlying the Forward-Looking Statements prove incorrect or should one or more risks or other factors materialize, including: (i) general economic, market and business conditions; (ii) market volatility that would affect the ability to enter or exit investments; (iii) commodity price fluctuations and uncertainties and, in particular the price of copper; and (iv) risks associated with the portfolio companies’ industries. The Forward-Looking Statements speak only as of the date hereof, unless otherwise specifically noted, and ODI Pharma does not assume any obligation to publicly update any Forward-Looking Statements, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

ODI Pharma AB: Publication of half-year report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available as an attached document to this press release and on the Compa


Original on Transparent.png
bottom of page